This is particularly important and interesting, given the failure of global NF-κB blockade in the clinic due to the complex roles and physiological importance of NF-κB, as well as the failure of all current therapies, including the combination of chemotherapy and PD-L1 blockade, in most cancer patients, including those with lung cancers. The gene discussed is NFKB1; the disease is cancer.